THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Drug nets $284m for MGH

Foreign royalty sale is second Enbrel windfall

Enbrel is used to treat rheumatoid arthritis. Enbrel is used to treat rheumatoid arthritis. ( )
By Christopher Rowland
Globe Staff / April 19, 2007

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Massachusetts General Hospital yesterday sold its rights to royalties on foreign sales of the rheumatoid arthritis drug Enbrel for $284 million, a move that eliminates its exposure to market risk and will help it build a research endowment. (Full article: 456 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass